GNH USA

Europe — EMA

Mitoxantron Ebewe (Mitoxantrone)

GNH USA supplies Mitoxantron Ebewe (Mitoxantrone), an anthracenedione for acute myeloid leukemia and acute lymphoblastic leukemia. Request a quote for supply.

Mitoxantrone

Request sourcing

1
Pack/s

What is Mitoxantrone?

Mitoxantrone, the active ingredient in Mitoxantron Ebewe, is an anthracenedione presented as an injectable solution for intravenous use. It is employed in the treatment of certain hematologic malignancies and solid tumors, including acute myeloid leukemia, acute lymphoblastic leukemia, metastatic breast cancer, and prostate cancer.

GNH USA supplies Mitoxantron Ebewe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. Our distribution network ensures timely delivery, regulatory compliance, and cold‑chain handling where required and product integrity throughout transit.

What is Mitoxantrone used for?

Mitoxantron Ebewe, an anthracenedione, is used in oncology to treat malignant diseases that involve rapid cell proliferation.

Acute myeloid leukemia: helps achieve remission by targeting proliferating leukemic cells. Acute lymphoblastic leukemia: contributes to disease control through DNA intercalation. Metastatic breast cancer: used to reduce tumor burden in advanced disease. Prostate cancer: employed in hormone‑refractory cases to inhibit tumor growth.

What are the side effects of Mitoxantrone?

Mitoxantron Ebewe may cause a range of adverse reactions, varying from frequent to rare but serious.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Fatigue: generalized tiredness. - Myelosuppression: reduced blood cell counts.

Serious or Rare Side Effects: - Cardiotoxicity: potential heart muscle damage. - Severe neutropenia: markedly low neutrophil count. - Hemorrhagic cystitis: bladder inflammation with bleeding.

What precautions apply to Mitoxantrone?

When using Mitoxantron Ebewe, clinicians should observe several precautions to minimize risks and ensure safe handling.

Monitor blood counts: perform regular complete blood count assessments. Assess cardiac function: conduct baseline and periodic echocardiograms. Avoid concurrent nephrotoxic drugs: limit exposure to agents that may impair kidney function. Hydration: maintain adequate fluid intake to reduce risk of bladder toxicity. Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Mitoxantrone interact with?

Mitoxantron Ebewe can interact with other medicines, affecting its efficacy or toxicity.

Major Interactions (Avoid): - Anthracyclines: combined use increases risk of cardiotoxicity. - High‑dose cyclophosphamide: may exacerbate myelosuppression. - Live vaccines: immunosuppression can reduce vaccine effectiveness.

Moderate Interactions (Monitor Closely): - Antifungal azoles: can alter drug metabolism and increase plasma levels. - CYP2C19 inhibitors: may affect clearance. - Radiotherapy: concurrent treatment may enhance tissue damage.

Frequently asked questions

What conditions is Mitoxantron Ebewe used to treat?+
Mitoxantron Ebewe contains mitoxantrone, an anthracenedione chemotherapy agent indicated for several malignant diseases. It is employed in the management of acute myeloid leukemia, acute lymphoblastic leukemia, metastatic breast cancer, and hormone‑refractory prostate cancer, where it helps to reduce tumor burden and achieve disease control as part of a broader treatment regimen prescribed by an oncologist.
How does mitoxantrone work in the body?+
Mitoxantrone exerts its antineoplastic effect by intercalating between DNA base pairs and stabilizing the DNA‑topoisomerase II complex, which blocks the resealing of DNA strands during replication and transcription. This leads to accumulation of double‑strand breaks, apoptosis of rapidly dividing cancer cells, and additional oxidative damage that enhances its cytotoxic activity.
What determines the dose of Mitoxantron Ebewe?+
The dose of Mitoxantron Ebewe is individualized by the treating physician based on factors such as the specific cancer type, disease stage, patient weight, renal and hepatic function, and prior chemotherapy exposure. The prescriber calculates the appropriate milligram per square meter (mg/m²) amount and schedules intravenous infusions according to established oncology protocols.
Is Mitoxantron Ebewe safe during pregnancy or breastfeeding?+
Safety data for mitoxantrone in pregnancy and lactation are limited, and the drug is classified as having an unknown pregnancy category. Because it can cross the placenta and be excreted in breast milk, it is generally avoided unless the potential therapeutic benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is essential before use in these populations.
How do I order Mitoxantron Ebewe from GNH USA?+
To request Mitoxantron Ebewe, visit the product page on gnh-usa.com and submit an enquiry specifying the required quantity. GNH USA works with hospitals, oncology centres, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and assistance with import documentation.
How does Mitoxantron Ebewe compare with other anthracenedones or similar chemotherapy agents?+
Mitoxantron Ebewe shares the core DNA‑intercalating mechanism of other anthracenedones such as anthracyclines, but it has a distinct toxicity profile, notably a higher risk of cardiotoxicity and myelosuppression. Compared with agents like doxorubicin, mitoxantrone may be chosen for patients who have previously received anthracyclines or who require a different spectrum of activity, always guided by oncologic assessment.
What are the recommended storage conditions for Mitoxantron Ebewe?+
Mitoxantron Ebewe should be stored in a refrigerator at 2 °C to 8 °C (36 °F to 46 °F). The vials must be kept in their original packaging, protected from light, and should never be frozen or shaken. Maintaining the cold chain during transport and handling preserves drug stability and potency.
How is Mitoxantron Ebewe administered to patients?+
The product is supplied as an injectable solution for intravenous infusion. Administration is performed by qualified healthcare professionals in a clinical setting, typically using an infusion pump or controlled drip over a prescribed period. The infusion rate and total dose are determined by the prescribing oncologist based on the treatment protocol and patient tolerance.
What are the most serious risks associated with Mitoxantron Ebewe?+
The most critical adverse events include cardiotoxicity, which can lead to irreversible heart damage; severe neutropenia and other forms of myelosuppression that increase infection risk; and hemorrhagic cystitis, a painful bladder condition that may cause bleeding. Patients should be monitored closely for cardiac function, blood counts, and urinary symptoms throughout therapy.
Who should not receive Mitoxantron Ebewe?+
Mitoxantron Ebewe is contraindicated in patients with known hypersensitivity to mitoxantrone or any component of the formulation. It should also be avoided in individuals with pre‑existing severe cardiac disease, uncontrolled infections, or significant bone‑marrow failure. Use in pregnant or nursing women is discouraged unless the potential benefit outweighs the risk, and it requires careful clinical judgment.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Mitoxantrone
Route
Intravenous Use
Manufacturer
Ebewe Pharma
Origin
EU

Related products

Mitoxan

Mitoxan

Mitoxantrone

Medicamerc S.A
EU
Mitoxantron "ebewe"

Mitoxantron "ebewe"

Mitoxantrone

Ebewe Pharma
EU
Mitoxantron Accord

Mitoxantron Accord

Mitoxantrone

Accord Healthcare B.V.
EU
Mitoxantron Ebewe

Mitoxantron Ebewe

Mitoxantrone

Ebewe Pharma
EU